Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 189

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4A
Chunk 189
---
. If we obtain regulatory approval for our Alpha DaRT technology or any other product candidates, we expect to
incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Furthermore, we expect
to continue to incur additional costs associated with operating as a public company. As a result, we will need substantial additional
funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from
product sales, if ever, we expect to fund our operations through public or private equity or debt financings or other sources, including
strategic collaborations. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable
terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on
our financial condition and our ability to develop our current product candidates, or any additional product candidates, if developed.

Because of the numerous risks
and uncertainties associated with therapeutics product development, we are unable to accurately predict the timing or amount of increased
expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenue from product sales,
we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may
be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.

As of December 31, 2024, we
had cash and cash equivalents short-term deposits and restricted deposits totaling $62,855. We believe that our existing cash and cash
equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least two years. We have based these
estimates on assumptions that may prove to be imprecise, and we may use our available capital resources sooner than we currently expect.
See “ Liquidity and Capital Resources.” Because of the numerous risks and uncertainties associated with the development
of our Alpha DaRT technology and any future product candidates, and because the extent to which we may enter into collaborations with
third parties for product development is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses
associated with completing the research and development of our Alpha DaRT technology or any future potential product candidates.

If we raise additional funds
through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to
our technologies, future revenue streams, research